Trump announces landmark trade deal with EU
On Wednesday, Stifel analysts began coverage of Compass Pathways (NASDAQ:CMPS), a company specializing in the development of psychedelic therapeutics, with a positive outlook. They issued a Buy rating and set a price target at $11.00, highlighting the potential for significant developments in the field of neuropsychiatry. Currently trading at $3.70, the stock has attracted strong analyst support, with an average consensus rating of "Strong Buy" according to InvestingPro data.
The analysts at Stifel expressed confidence in the future of psychedelic treatments, noting that there is a growing consensus among key stakeholders, including the FDA, CNS thought leaders, and physicians, that psychedelics are likely to emerge as a major drug class. They pointed to the success of Spravato, a treatment for depression, as validation that intermittent psychedelic treatment models have the potential to be scaled effectively.
Compass Pathways is currently focusing on advancing its psilocybin therapy, COMP360, through clinical trials. Stifel analysts believe that the company is well-positioned to reduce the risks associated with COMP360 in the upcoming two phase 3 studies. The first of these studies is expected to release results in the second quarter of 2025. InvestingPro data shows the company maintains a strong liquidity position with a current ratio of 8.91, though it is currently burning through cash with negative free cash flow of $105 million over the last twelve months.
Shares of Compass Pathways are trading below their initial public offering price from 2020, with the stock down over 65% in the past year and currently near its 52-week low of $3.17. According to Stifel, this presents an attractive buying opportunity for investors ahead of anticipated positive clinical data and in the context of a supportive regulatory environment. The analysts’ outlook is based on the premise that forthcoming clinical results will likely be favorable, considering the alignment with the FDA’s perspective on psychedelic treatments. For deeper insights into CMPS’s valuation and 12 additional ProTips, visit InvestingPro to access the comprehensive Pro Research Report.
In other recent news, Compass Pathways has been the subject of notable financial and strategic developments. H.C. Wainwright revised its price target for Compass Pathways, reducing it from $60 to $45, while maintaining a Buy rating. This change follows discussions regarding the progress of COMP360, the company’s psilocybin therapy, and a recent capital raise of $150 million, which extends the company’s financial runway into 2026. The funds are expected to support ongoing trials for treatment-resistant depression (TRD) and potentially expand into other areas. Meanwhile, Rodman & Renshaw also maintained a Buy rating but significantly lowered the price target from $30 to $9, following Compass Pathways’ announcement of a financing plan that could raise up to $355 million. This plan involves issuing new shares and warrants, potentially doubling the company’s share count. Despite the dilution, Compass Pathways is projected to have around $400 million in cash reserves by mid-2025, ahead of the anticipated results from the first Phase 3 trial of COMP360. Rodman & Renshaw adjusted the commercial launch timeline for COMP360 in the U.S. from 2027 to 2029 due to enrollment delays.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.